Dissection of Agonistic and Blocking Effects of CD200 Receptor Antibodies

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Akkaya, Munir ^a   Aknin, Marie Laure ^a   Akkaya, Billur ^b   Barclay, A Neil ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR; CD200 RECEPTOR ANTIBODY; CD200 RECEPTOR LIGAND A; CD200 RECEPTOR LIGAND C; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX110; MONOCLONAL ANTIBODY OX131; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BIOCHEMISTRY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG RECEPTOR BINDING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, SURFACE; CROSS REACTIONS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; MYELOID CELLS; PROTEIN ISOFORMS; RATS; RECEPTORS, CELL SURFACE; TRANSFECTION;

EID: 84877788071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063325     Document Type: Article

References (45)

1. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, et al. (2003) Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 171: 3034-3046.
2. Voehringer D, Rosen DB, Lanier LL, Locksley RM, (2004) CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells. J Biol Chem 279: 54117-54123.
3. Mihrshahi R, Barclay AN, Brown MH, (2009) Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 183: 4879-4886.
4. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH, (2004) Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 173: 6786-6793.
5. Mihrshahi R, Brown MH, (2010) Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling. J Immunol 185: 7216-7222.
6. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, et al. (2000) Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13: 233-242.
7. Barclay AN, Brown MH, (2006) The SIRP family of receptors and immune regulation. Nat Rev Immunol 6: 457-464.
8. Chao MP, Weissman IL, Majeti R, (2012) The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24: 225-232.
9. Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, et al. (2011) CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25: 792-799.
10. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, et al. (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178: 5595-5605.
11. Rygiel TP, Meyaard L (2012) CD200R signaling in tumor tolerance and inflammation: A tricky balance. Curr Opin Immunol.
12. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, et al. (2011) CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 108: 18342-18347.
13. Akkaya M, Barclay AN, (2013) How do pathogens drive the evolution of paired receptors? Eur J Immunol 43: 303-313.
14. Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, et al. (2004) CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 172: 7744-7749.
15. Hatherley D, Cherwinski HM, Moshref M, Barclay AN, (2005) Recombinant CD200 protein does not bind activating proteins closely related to CD200 receptor. J Immunol 175: 2469-2474.
16. Akkaya M, Barclay AN, (2010) Heterogeneity in the CD200R paired receptor family. Immunogenetics 62: 15-22.
17. Brooke G, Holbrook JD, Brown MH, Barclay AN, (2004) Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J Immunol 173: 2562-2570.
18. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109: 6662-6667.
19. Lanier LL, Corliss B, Wu J, Phillips JH, (1998) Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8: 693-701.
20. Mizushima S, Nagata S, (1990) pEF-BOS, a powerful mammalian expression vector. Nucl Acids Res 18: 5322.
21. Tomlinson DC, L'Hote CG, Kennedy W, Pitt E, Knowles MA, (2005) Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 65: 10441-10449.
22. Mond JJ, Brunswick M (2003) Proliferative Assays for B cell Function. Curr Protocols Immunol. 3.10.11-13.10.18.
23. Reichlin A, Yokoyama WM, (1998) Natural killer cell proliferation induced by anti-NK1.1 and IL-2. Immunol Cell Biol 76: 143-152.
24. Cash JL, Hart R, Russ A, Dixon JP, Colledge WH, et al. (2008) Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 205: 767-775.
25. Cash JL, White GE, Greaves DR, (2009) Chapter 17. Zymosan-induced peritonitis as a simple experimental system for the study of inflammation. Methods Enzymol 461: 379-396.
26. Cantor AB, Iwasaki H, Arinobu Y, Moran TB, Shigematsu H, et al. (2008) Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J Exp Med 205: 611-624.
27. Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, et al. (1999) Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res 59: 2802-2805.
28. Dyer KD, Czapiga M, Foster B, Foster PS, Kang EM, et al. (2007) Eosinophils from lineage-ablated Delta dblGATA bone marrow progenitors: the dblGATA enhancer in the promoter of GATA-1 is not essential for differentiation ex vivo. J Immunol 179: 1693-1699.
29. Boudakov I, Liu J, Fan N, Gulay P, Wong K, et al. (2007) Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 84: 251-257.
30. Jiang L, Barclay AN, (2009) New assay to detect low-affinity interactions and characterization of leukocyte receptors for collagen including leukocyte-associated Ig-like receptor-1 (LAIR-1). Eur J Immunol 39: 1167-1175.
31. Jiang L, Barclay AN, (2010) Identification of leucocyte surface protein interactions by high-throughput screening with multivalent reagents. Immunology 129: 55-61.
32. Swift S, Lorens J, Achacoso P, Nolan GP (2001) Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol Chapter 10: Unit 10 17C.
33. Clarkson NG, Brown MH, (2009) Inhibition and activation by CD244 depends on CD2 and phospholipase C-gamma1. J Biol Chem 284: 24725-24734.
34. Ortaldo JR, Mason A, Overton R, (1986) Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164: 1193-1205.
35. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, et al. (2008) A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 9: 1074-1083.
36. Kojima T, Obata K, Mukai K, Sato S, Takai T, et al. (2007) Mast cells and basophils are selectively activated in vitro and in vivo through CD200R3 in an IgE-independent manner. J Immunol 179: 7093-7100.
37. Waldmann H, Cobbold SP, Fairchild P, Adams E, (2001) Therapeutic aspects of tolerance. Curr Opin Pharmacol 1: 392-397.
38. Carter PJ, (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317: 1261-1269.
39. Kretz-Rommel A, Bowdish KS, (2008) Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opin Biol Ther 8: 5-15.
40. Pallasch CP, Ulbrich S, Brinker R, Hallek M, Uger RA, et al. (2009) Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 33: 460-464.
41. Torrero MN, Larson D, Hubner MP, Mitre E, (2009) CD200R surface expression as a marker of murine basophil activation. Clin Exp Allergy 39: 361-369.
42. Caserta S, Nausch N, Sawtell A, Drummond R, Barr T, et al. (2012) Chronic infection drives expression of the inhibitory receptor CD200R, and its ligand CD200, by mouse and human CD4 T cells. PLoS One 7: e35466.
43. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA, (1995) Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol 247: 443-458.
44. Cherwinski HM, Murphy CA, Joyce BL, Bigler ME, Song YS, et al. (2005) The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 174: 1348-1356.
45. Gorczynski RM, Chen Z, Lee L, Yu K, Hu J, (2002) Anti-CD200R ameliorates collagen-induced arthritis in mice. Clin Immunol 104: 256-264.